Role of surgical resection for non-colorectal non-neuroendocrine liver metastases

Table 7 Summary of studies with ≥ 40 patients who underwent hepatectomy for liver metastasis from melanoma

Ref.	Year	Period	No. of patients	Ocular/cutaneous	MST (mo) (ocular/cutaneous)	3-ysr (%)	5-ysr (%)	Factors associated with worse overall survival
Adam et al[10]1	2006	1983-2004	148	104/44	19/27	NR	21 (ocular)/22 (cutaneous)	NR
Pawlik et al[44]	2006	1988-2004	40	16/24	28 [29 (ocular)/24 (cutaneous)]	62 (ocular)/48 (cutaneous) (2-yr)	11 (21 (ocular)/0 (cutaneous))	Cutaneous melanoma, no preoperative chemotherapy (in cutaneous melanoma) (univariable)
Mariani et al[45]	2009	1991-2007	255 (R2 = 157)	255/0	14 (27 mo after R0 resection)	NR	7	Interval from primary tumor diagnosis ≤ 24 mo, R1 and R2, number of the metastases > 4, miliary disease
Mariani et al[46]	2016	2000-2013	70 (inclding 13 concomitant with RFA)	70/0	27 (hepatectomy), 28 (+RFA)	NR	NR	NR

¹As a part of the report of on-colorectal non-neuroendocrine liver metastases. MST: Median survival time; ysr: Year survival rate; NR: Not reported.